<li>abobotulinumtoxina<p>verapamil increases effects of abobotulinumtoxina by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>agrimony<p>agrimony increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>alfuzosin<p>verapamil will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alosetron<p>verapamil will increase the level or effect of alosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>alvimopan<p>verapamil will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>ambrisentan<p>verapamil will increase the level or effect of ambrisentan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>amitriptyline<p>verapamil will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>verapamil increases levels of amitriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>amlodipine<p>verapamil will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>amoxapine<p>verapamil increases levels of amoxapine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>antipyrine<p>verapamil will increase the level or effect of antipyrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>armodafinil<p>verapamil will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>verapamil will increase the level or effect of armodafinil by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>asenapine<p>verapamil will increase the level or effect of asenapine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>aspirin<p>verapamil increases effects of aspirin by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>aspirin rectal<p>verapamil increases effects of aspirin rectal by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>verapamil increases effects of aspirin/citric acid/sodium bicarbonate by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>atracurium<p>verapamil increases effects of atracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>balsalazide<p>verapamil increases effects of balsalazide by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>bosentan<p>verapamil will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>brimonidine<p>brimonidine increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>caffeine<p>verapamil will increase the level or effect of caffeine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>cevimeline<p>verapamil will increase the level or effect of cevimeline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>choline magnesium trisalicylate<p>verapamil increases effects of choline magnesium trisalicylate by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>cisatracurium<p>verapamil increases effects of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>clarithromycin<p>verapamil will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomethiazole<p>verapamil will increase the level or effect of clomethiazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>clomipramine<p>verapamil will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>verapamil increases levels of clomipramine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>colesevelam<p>colesevelam decreases levels of verapamil by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. (Sustained release form of verapamil).</p></li><li>cornsilk<p>cornsilk increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>dapsone<p>verapamil will increase the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>delavirdine<p>verapamil will increase the level or effect of delavirdine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>desipramine<p>verapamil increases levels of desipramine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>diflunisal<p>verapamil increases effects of diflunisal by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>docetaxel<p>verapamil will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>donepezil<p>verapamil will increase the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>dosulepin<p>verapamil increases levels of dosulepin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>doxepin<p>verapamil increases levels of doxepin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>dutasteride<p>verapamil will increase the level or effect of dutasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>verapamil will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>encainide<p>verapamil increases levels of encainide by decreasing metabolism. Minor/Significance Unknown.</p></li><li>etoricoxib<p>verapamil will increase the level or effect of etoricoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>eucalyptus<p>verapamil will increase the level or effect of eucalyptus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fexofenadine<p>verapamil will increase the level or effect of fexofenadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>finasteride<p>verapamil will increase the level or effect of finasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>fo-ti<p>fo-ti increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>forskolin<p>forskolin increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>frovatriptan<p>verapamil will increase the level or effect of frovatriptan by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>galantamine<p>verapamil will increase the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>hydrochlorothiazide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>imatinib<p>verapamil will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>imipramine<p>verapamil increases levels of imipramine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>incobotulinumtoxina<p>verapamil increases effects of incobotulinumtoxina by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>isradipine<p>verapamil will increase the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>itraconazole<p>verapamil will increase the level or effect of itraconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ketoconazole<p>verapamil will increase the level or effect of ketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>lily of the valley<p>verapamil, lily of the valley.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>lithium<p>verapamil increases toxicity of lithium by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of neurotoxicity.</p></li><li>lofepramine<p>verapamil increases levels of lofepramine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>lofexidine<p>lofexidine increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>loratadine<p>verapamil will increase the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>maitake<p>maitake increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>maprotiline<p>verapamil increases levels of maprotiline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>memantine<p>memantine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>mesalamine<p>verapamil increases effects of mesalamine by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>metformin<p>metformin will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>methyclothiazide<p>methyclothiazide will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>metipranolol ophthalmic<p>metipranolol ophthalmic increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>mianserin<p>verapamil increases levels of mianserin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>mibefradil<p>verapamil will increase the level or effect of mibefradil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>midodrine<p>midodrine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>montelukast<p>verapamil will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nifedipine<p>verapamil will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nimodipine<p>verapamil will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nitrendipine<p>verapamil will increase the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>nortriptyline<p>verapamil increases levels of nortriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>octacosanol<p>octacosanol increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>ofloxacin<p>ofloxacin will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>onabotulinumtoxina<p>verapamil increases effects of onabotulinumtoxina by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>ondansetron<p>verapamil will increase the level or effect of ondansetron by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.<span><br><br></span>verapamil will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>oxcarbazepine<p>verapamil decreases levels of oxcarbazepine by increasing metabolism. Minor/Significance Unknown.</p></li><li>oxybutynin<p>verapamil will increase the level or effect of oxybutynin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>paclitaxel<p>verapamil will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>paclitaxel protein bound<p>verapamil will increase the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pancuronium<p>verapamil increases effects of pancuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>parecoxib<p>verapamil will increase the level or effect of parecoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pimozide<p>verapamil will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>pioglitazone<p>verapamil will increase the level or effect of pioglitazone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>porfimer<p>verapamil decreases levels of porfimer by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>pramipexole<p>pramipexole will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>propafenone<p>verapamil will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>protriptyline<p>verapamil increases levels of protriptyline by decreasing metabolism. Minor/Significance Unknown.</p></li><li>quinine<p>verapamil will increase the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.<span><br><br></span>quinine will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ramelteon<p>verapamil will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ranitidine<p>verapamil will increase the level or effect of ranitidine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>rapacuronium<p>verapamil increases effects of rapacuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>reishi<p>reishi increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>riluzole<p>verapamil will increase the level or effect of riluzole by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>rimabotulinumtoxinb<p>verapamil increases effects of rimabotulinumtoxinb by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>rocuronium<p>verapamil increases effects of rocuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>salicylates (non-asa)<p>verapamil increases effects of salicylates (non-asa) by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>salsalate<p>verapamil increases effects of salsalate by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>saxagliptin<p>verapamil will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>shepherd's purse<p>shepherd's purse, verapamil. Other (see comment). Minor/Significance Unknown. 
Comment: Theoretically, shepherd's purse may interfere with BP control.</p></li><li>succinylcholine<p>verapamil increases effects of succinylcholine by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>verapamil increases effects of sulfasalazine by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>tacrine<p>verapamil will increase the level or effect of tacrine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>telithromycin<p>verapamil will increase the level or effect of telithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>tizanidine<p>tizanidine increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.</p></li><li>trazodone<p>verapamil increases levels of trazodone by decreasing metabolism. Minor/Significance Unknown.</p></li><li>treprostinil<p>treprostinil increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>triamterene<p>triamterene will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>trimethoprim<p>trimethoprim will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>trimipramine<p>verapamil increases levels of trimipramine by decreasing metabolism. Minor/Significance Unknown.</p></li><li>troglitazone<p>troglitazone decreases levels of verapamil by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>troleandomycin<p>verapamil will increase the level or effect of troleandomycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>tubocurarine<p>verapamil increases effects of tubocurarine by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>vecuronium<p>verapamil increases effects of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon.</p></li><li>verteporfin<p>verapamil increases levels of verteporfin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>vesnarinone<p>verapamil will increase the level or effect of vesnarinone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vinblastine<p>verapamil will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine<p>verapamil will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vincristine liposomal<p>verapamil will increase the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>vinorelbine<p>verapamil will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>willow bark<p>verapamil increases effects of willow bark by unknown mechanism. Minor/Significance Unknown. Enhanced antiplatelet activity.</p></li><li>zaleplon<p>verapamil will increase the level or effect of zaleplon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>ziprasidone<p>verapamil will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zolpidem<p>verapamil will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>zonisamide<p>verapamil will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li>